Clorox CEO Succession: Unilever's Fabian Garcia to Lead in January

A successor named, five months after the search began

Clorox has picked its next chief executive. The board has appointed Fabian Garcia, who currently runs Unilever's Personal Care business, as CEO effective January 5, 2027. He will replace Linda Rendle, who said in May that she would step down for health reasons.2 Rendle stays on as chair and CEO until Garcia arrives. On that date she leaves both the CEO job and the board, and she will then serve as an adviser through April 2, 2027.29

The announcement settles a question that had hung over the Oakland-based maker of bleach, Brita filters, Glad bags, Kingsford charcoal and Hidden Valley dressing since late spring.2 The search was led by an independent CEO search committee of the board, working with an outside executive search firm.14

This is not a founder stepping aside. Clorox has been headquartered in Oakland since 1913.14 Rendle is a career insider who spent 23 years at the company, the last six as CEO.11 What makes her exit unusual is its cause. In a personal note on the company's website, she said she is cancer-free after a diagnosis of early-stage breast cancer. She added that the side effects of ongoing treatment to prevent recurrence led her to rethink how she cares for her health and family.11

Who Fabian Garcia is

Garcia has spent his whole career in consumer packaged goods. He joined Unilever in 2020 and has held several senior roles there, including president of Unilever North America. He now sits on the Unilever Leadership Executive team.2 Before Unilever he was CEO of Revlon and chief operating officer for Global Innovation and Growth at Colgate-Palmolive. Earlier, he held global leadership roles at Procter & Gamble.29 According to a summary of the company's regulatory filing, he is 66, has run Unilever's personal care group since 2022, and led Revlon from 2016 to 2018.12 He sits on the Wells Fargo board and previously served as a director of Kimberly-Clark and Arrow Electronics.4

The reports differ on one detail. One outlet describes Garcia as a former Unilever Personal Care president.5 Most reports, and the company's own release, say he still holds the job.136 The company's wording should be treated as correct. Garcia still has a role to leave at Unilever, and that matters for the timing of his January start.

Lead independent director Matthew Shattock said the board valued Garcia's record running large consumer businesses, pushing innovation and handling complicated, shifting customer and channel dynamics. He said Garcia can build on what Rendle put in place and strengthen execution.13 Garcia's own statement was notably candid for an incoming CEO. He said there is more work ahead to strengthen performance and realize the company's full potential.9

The board reshuffle: chair and CEO split

The change at the top of the board may matter as much as the new CEO. Rendle held both the chair and CEO titles, and those roles will now be separated.3 When Garcia joins the board in January, Shattock, a former board chair who is currently lead independent director, will become independent chair.2 The company's release describes this as Shattock resuming the chair role, not taking on a new one.3 Filing summaries say he will receive an extra $225,000 annual retainer for the expanded role.12

The split is a familiar step for boards bringing in an outside CEO. One analysis described it as a governance shift meant to strengthen oversight while the new chief settles in.12 There is a practical reading too. Garcia arrives from outside Clorox, and an experienced independent chair who already knows the company gives the board a steady hand while the new CEO learns it.

The pay package

The filing shows an unusual pay structure. Garcia's annual base salary is just $100,000, with a target annual short-term incentive of $2 million paid in company stock.12 He is eligible for a long-term incentive award with a target value of $4.55 million for the rest of fiscal 2027. From September 2027, that annual target rises to $9.1 million.512 He also receives a one-time $11 million grant of restricted stock units, vesting evenly over three years, to replace equity he gives up by leaving his current employer.512

The low cash salary does not mean a pay cut. Clorox has set a $1.25 million peer-median salary benchmark for salary-linked benefits, perks and severance calculations.5 In practice, almost all of Garcia's reward depends on the share price. The most likely reading is that the board wants the new CEO's wealth tied directly to a turnaround in the stock.

Rendle keeps her $1.35 million base salary during the advisory period. Her departure counts as a "Retirement" under her outstanding long-term awards, so they keep vesting on their original schedules. She will not get new equity grants while she advises.12

Why it matters: a company still working to recover

The tone of the announcement says a lot. Garcia's "more work ahead" line9 matches how Rendle described the business in May. Back then she said management was focused on restoring profitable growth and market share in what she called a challenging operating environment.14 Her May letter listed what the company had been through during her six years as CEO: the pandemic, supply chain disruption, inflation, changing consumer behavior, geopolitical uncertainty and a cyberattack.11

Shattock credited Rendle with modernizing Clorox's digital and operational systems and shifting the portfolio toward faster-growing health and hygiene categories.14 Even so, the market's view stayed cautious. At the time of the May announcement, one AI-driven assessment rated the stock neutral. It cited high leverage, negative shareholder equity, weakening cash-flow momentum and a sustained downtrend in the share price. It also pointed to possible gains from stabilizing the company's ERP (enterprise resource planning) system and from synergies tied to GOJO, the Purell maker.15 Clorox closed at $86.84 recently, for a market capitalization of about $10.5 billion.3 Another feed showed the shares at $87.96, up 1.29%, with a dividend yield of 4.6%.7

The early market reaction looks muted. One automated analysis rated the news neutral on both impact and sentiment.3 Another called it a dated, detailed version of a change investors already knew was coming. It said a bigger catalyst would be concrete strategic or financial targets from Garcia, or changes to guidance or portfolio priorities.8 That is a fair reading. The surprise came in May. The real test is what Garcia does after January.

Where the reporting agrees, and what it leaves out

The coverage agrees on the key facts: the January 5 start date, the April 2 end of Rendle's advisory role, Shattock's return as chair, and Garcia's career at P&G, Colgate, Revlon and Unilever.14710 Most reports closely follow the company's release. The pay details come mainly from outlets that read the filing itself.512

The coverage pays less attention to the Revlon part of Garcia's record. Outlets list it as a credential without asking how that company fared under his leadership. Investors will probably ask, since Clorox is hiring him partly for his operating track record. Reports also say little about whether Clorox considered internal candidates, even though Rendle praised the company's "deep bench" of leaders in May.11 Choosing an outsider over that bench suggests the board wanted a fresh view more than continuity. That reading fits Garcia's own focus on improving performance.

What comes next

The next event is close. Clorox reports first-quarter fiscal 2027 results on Monday, November 2. Rendle and CFO Luc Bellet will host the analyst call, not Garcia.2 So investors will hear the outlook from a CEO who is leaving, about two months before her successor starts.9 Any guidance from that call is effectively Rendle's to hand over. Garcia's first real chance to set his own agenda will probably come with the following quarter's results.

Overall, the board ran an orderly process with a clear timeline. It hired a seasoned outsider, split the chair and CEO roles, and paid him almost entirely in stock. The setup is sound. The open question is whether a 66-year-old industry veteran can deliver the profitable growth that both he and his predecessor say the company still needs.